A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
BA-2664
Glycine betaine
The therapeutic efficacy of Revefenacin can be decreased when used in combination with Glycine betaine.
BA-2664
Aprotinin
The therapeutic efficacy of Revefenacin can be decreased when used in combination with Aprotinin.
BA-2664
Regramostim
The therapeutic efficacy of Revefenacin can be decreased when used in combination with Regramostim.
BA-2664
Phenserine
The therapeutic efficacy of Revefenacin can be decreased when used in combination with Phenserine.
BA-2664
Huperzine A
The therapeutic efficacy of Revefenacin can be decreased when used in combination with Huperzine A.
BA-2664
Thiotepa
The therapeutic efficacy of Revefenacin can be decreased when used in combination with Thiotepa.
BA-2664
1,10-Phenanthroline
The therapeutic efficacy of Revefenacin can be decreased when used in combination with 1,10-Phenanthroline.
BA-2664
Cannabinol
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Cannabinol.
BA-2664
Palmidrol
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Palmidrol.
BA-2664
WIN 55212-2
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with WIN 55212-2.
BA-2664
Surinabant
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Surinabant.
BA-2664
Ibipinabant
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Ibipinabant.
BA-2664
Ajulemic acid
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Ajulemic acid.
BA-2664
GW842166
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with GW842166.
BA-2664
Taranabant
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Taranabant.
BA-2664
Rimonabant
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Rimonabant.
BA-2664
SLV319
The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with SLV319.
BA-2664
Epitizide
The serum concentration of Epitizide can be increased when it is combined with Revefenacin.
BA-2664
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Revefenacin.
BA-2664
Cimetropium
The risk or severity of adverse effects can be increased when Revefenacin is combined with Cimetropium.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3